• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (TSV: DMT )

    N/A UNCHANGED
    Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about DMT

    < Previous 1 2 Next >
    Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
    From Cybin Inc.
    Via Business Wire
    Small Pharma Reports Fiscal Second Quarter 2024 Highlights
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Obtains Final Order Approving Arrangement
    From Cybin Inc.
    Via Business Wire
    Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
    From Small Pharma Inc.
    Via GlobeNewswire
    Cybin to Acquire Small Pharma Inc.
    - All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for... 
    Via Newsfile
    Topics Intellectual Property
    Exposures Intellectual Property
    Cybin to Acquire Small Pharma Inc.
    From Cybin Inc.
    Via Business Wire
    Small Pharma Reports Fiscal First Quarter 2024 Highlights
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Announces SPL028 R&D Strategy Update
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Announces Management Team Change
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Announces Significant Developments In Intellectual Property Portfolio
    5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions 
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
    Chief Medical and Scientific Officer, Dr. Carol Routledge, will deliver a poster presentation on data from the Company’s SPL026 Phase IIa clinical trial in patients with Major Depressive Disorder 
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
    Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months 
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
    Company will also host a cocktail reception on Tuesday, March 7 
    From Small Pharma Inc.
    Via GlobeNewswire
    First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Reports Fiscal Third Quarter 2023 Highlights
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
    From Small Pharma Inc.
    Via GlobeNewswire
    First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
    Study will compare the profile of intramuscular versus intravenous SPL026 administration 
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
    From Small Pharma Inc.
    Via GlobeNewswire
    First Patient Dosed in Small Pharma’s Drug Interaction Study
    Open-label study will assess the interaction between SSRI antidepressants and SPL026 
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma To Support University College London Research Project on Neuroplasticity
    Small Pharma will provide SPL026 for the brain-imaging study, which seeks to explore how psychedelic-induced brain changes impact cognition, behaviour and well-being 
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma to Participate in November Investor and Healthcare Conferences
    From Small Pharma Inc.
    Via GlobeNewswire
    Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028
    From Small Pharma Inc.
    Via GlobeNewswire
    Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio
    From Small Pharma Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.